Kymera Therapeutics Inc. (KYMR)
NASDAQ: KYMR
· Real-Time Price · USD
42.59
-1.03 (-2.36%)
At close: Aug 19, 2025, 3:59 PM
42.57
-0.05%
After-hours: Aug 19, 2025, 04:25 PM EDT
-2.36% (1D)
| Bid | 42.1 |
| Market Cap | 3.05B |
| Revenue (ttm) | 58.88M |
| Net Income (ttm) | -240.88M |
| EPS (ttm) | -3.49 |
| PE Ratio (ttm) | -12.2 |
| Forward PE | -10.61 |
| Analyst | Buy |
| Ask | 45 |
| Volume | 437,325 |
| Avg. Volume (20D) | 886,517 |
| Open | 43.56 |
| Previous Close | 43.62 |
| Day's Range | 42.12 - 44.06 |
| 52-Week Range | 19.45 - 53.27 |
| Beta | 2.18 |
About KYMR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KYMR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for KYMR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Kymera Therapeutics has released their quartely earnings
on Aug 11, 2025:
Next Earnings Release
Kymera Therapeutics Inc. is scheduled to release its earnings on
Oct 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-7.24%
Kymera Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
1 month ago
-1.42%
Kymera Therapeutics shares are trading lower after the company announced a $250 million public offering.
1 month ago · proactiveinvestors.com
Gilead partners with Kymera to develop novel cancer therapyGilead Sciences Inc (NASDAQ:GILD, ETR:GIS) and Kymera Therapeutics (NASDAQ:KYMR) have entered into an exclusive option and license agreement focused on developing a novel cancer treatment targeting cy...
